Short answer
Allogene Therapeutics, Inc. (ALLO) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 8.01 (Other Events). Interim futility analysis supports cema-cel activity, with MRD negativity of 58.3% versus 16.7% for observation.
Allogene Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Interim futility analysis supports cema-cel activity, with MRD negativity of 58.3% versus 16.7% for observation
- 41.6-percentage-point MRD clearance advantage exceeds the 25–30% literature threshold associated with potential clinical benefit
- Day 45 ctDNA declined 97.7% median with cema-cel versus a 26.6% median increase under observation
- Favorable early safety profile, with no CRS, ICANS, GvHD, or treatment-related serious adverse events among 12 treated patients
- ALPHA3 targets approximately 220 patients, with interim EFS analysis expected mid-2027 and primary analysis mid-2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Allogene Therapeutics, Inc. 8-K filings
Get the next ALLO 8-K as it lands
Follow ALLO for push alerts, or ask the research agent what this filing means.